A network meta-analysis of 18 studies including 156,690 patients with T2DM reported that SGLT2 inhibitors were related to a lower risk of AKI compared with placebo (OR = 0.76). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.